Cerus Raises 2026 Outlook After 24% Q1 Product Revenue Jump as INT200 Filing Nears

Overview

• Cerus, which reported Thursday on its earnings call, said first‑quarter product revenue rose 24% to $53.7 million.
• The company lifted its 2026 product revenue guidance to $227–$231 million and increased IFC revenue guidance to $22–$24 million.
• Executives reported broader adoption of INTERCEPT, a system that reduces pathogens in blood components to make transfusions safer, with higher North American platelet kit volumes and a multi‑year contract renewal in France.
• Regulatory work is moving forward, with management saying the INT200 device will be filed imminently for U.S. premarket approval and with plans progressing for Intercept Red Blood Cells.
• Cerus expects to remain adjusted‑EBITDA positive and outlined a push toward GAAP profitability under incoming chief executive Vivek Jayaraman.